COX-2 class reunion? Prexige, Arcoxia inch forward
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Merck's resubmitted NDA for Arcoxia (etoricoxib) seeks a narrowed indication for treatment of osteoarthritis only; the original NDA for the follow-on to Merck's now-withdrawn Vioxx, submitted in 2003, sought uses in OA, RA, chronic low-back pain, acute pain, dysmenorrhea, gouty arthritis and ankylosing spondylitis. Merck anticipates a six-month review, with a user fee goal at the end of April 2007. Novartis plans to resubmit its COX-2 inhibitor Prexige (lumiracoxib) in the first half of 2007; the NDA has been "not approvable" since 2003. On Nov. 7, Novartis announced approval of Prexige for osteoarthritis in the European Union and Canada...
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.